Keros Therapeutics Inc
KROS
NASDAQ
Biotechnology
$10.10
USD
-0.56 (-5.25%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $215.92M
Volume 315.3K
Revenue
$15.01M
TTM
-93.6%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-83.16M
TTM
-543.0%
YoY
Operating Cash Flow
$-47.99M
TTM
-187.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 18.2 | 14.3 | 0.4 | 0.4 | 0.0 |
YoY Growth | +49002.7% | +3575.8% | -87.3% | -99.8% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 18.2 | 14.3 | 0.4 | 0.4 | 0.0 |
Selling, General & Administrative | 14.5 | 10.1 | 11.7 | 10.1 | 8.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 58.0 | 29.6 | 29.7 | 26.2 | 30.9 |
Operating Income | -39.8 | -15.4 | -29.3 | -25.9 | -30.9 |
EBITDA | -39.4 | -15.0 | -28.9 | -25.5 | -30.5 |
Other Income / Expense | -0.2 | -0.3 | 0.3 | -0.2 | -0.1 |
Total Other Income / Expense | 6.9 | 6.7 | 4.3 | 2.2 | 2.2 |
Income Before Income Taxes | -32.9 | -8.7 | -25.0 | -23.7 | -28.7 |
Income Taxes | -2.2 | -1.4 | -1.5 | 0.0 | 0.0 |
Net Income | -30.7 | -7.3 | -23.5 | -23.7 | -28.7 |
Consolidated Net Income / Loss | -30.7 | -7.3 | -23.5 | -23.7 | -28.7 |
Net Income Attributable to Common Shareholders | -30.7 | -7.3 | -23.5 | -23.7 | -28.7 |
Basic EPS | -$0.76 | -$0.18 | -$0.87 | -$1.21 | -$1.45 |
Diluted EPS | -$0.76 | -$0.18 | -$0.80 | -$1.21 | -$1.45 |
Basic Shares Outstanding | 40.6M | 40.6M | 27.1M | 19.6M | 19.8M |
Diluted Shares Outstanding | 40.6M | 40.6M | 29.2M | 19.6M | 19.8M |